Proniras

About:

Proniras focuses on development of a new parenteral medical countermeasure (MCM) to treat seizures and brain injury.

Top Investors: ARCH Venture Partners, WRF Capital, Accelerator Life Science Partners, Watson Fund

Description:

Proniras Corp is an operator of a biomedical company intended to develop drugs. The company's biomedical service has already demonstrated preclinical efficacy in treating nerve agent-induced seizures, as well as in studies of rodents exposed to the chemical weapon soman, which is more toxic than sarin gas, enabling medical researchers to continue their research work and discover drugs. It was founded in 2016 and is headquartered in Seattle, Washington.

Total Funding Amount:

$8.95M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Seattle, Washington, United States

Founded Date:

2016-01-01

Contact Email:

info(AT)proniras.com

Founders:

Christopher Toombs

Number of Employees:

1-10

Last Funding Date:

2024-02-01

IPO Status:

Private

Industries: